Name: National EBS Association (NEBSA) 2014 Annual Meeting
Start: 2014-02-17T05:00

Why Fish

Diversity, Equity & Inclusion

Pro Bono & Social Responsibility

Legal Operations

Pricing

Legal Project Management

Knowledge Management

eDiscovery

Legal Technology Services

Trademark, Copyright & Media Litigation

Trade Secret Litigation

Appellate

Chancery & Corporate Governance

Post-Grant

Inter Partes Review

Post-Grant Review

Ex Parte Reexamination

Supplemental Examination

Patent

Patent Prosecution

Strategic Patent Counseling & Opinions

Patent Portfolio Management

Unitary Patent & Unified Patent Court

IP Licensing, Transactions & Agreements

Trademark & Copyright Counseling & Prosecution

Strategic Counseling, Registration & Opinions

Advertising & Marketing

Domain Names & Internet

TTAB Oppositions & Cancellations

Digital Millennium Copyright Act

Transactions & Agreements

Regulatory & Government Affairs

Communications & Spectrum Regulation

Drug & Medical Device Regulation

mHealth & Telemedicine

Privacy & Data Security

Industries

Electrical & Computer Technology

Artificial Intelligence

Digital Health

Digital Media & E-Commerce

Financial, Business & FinTech Services

Biotech & Diagnostics

Medical Devices

Pharmaceuticals

Academic Research & Medical Centers

Transportation, Aerospace & Defense

Post-Grant Annual Reports

Hosts

Name

Ed Lavergne

Person title

Senior Principal

Principal Edwin Lavergne (DC) will present at the NEBSA 2014 Annual Meeting.

National EBS Association (NEBSA) 2014 Annual Meeting

Hosts

Practising Law Institute Developments in Pharmaceutical and Biotech Patent Law 2024

Consero IP Forum for Life Sciences 2024

Berkeley-Stanford Advanced Patent Law Institute 2024

Practising Law Institute Patenting Blockchain and Distributed Ledger Technologies 2024

ACC San Francisco Bay Area Program: IP Challenges and Strategies for Startups

How a Second Trump Presidency Could Shape IP

Hatch-Waxman 101

Biologics and Biosimilars Landscape: IP, Policy, and Market Developments

Legal Alert: Biden Administration Proposes March-In Rights Framework for Pharmaceutical Patents in Effort to Lower Drug Prices

Senior Principal Terry Mahn Authors Medical Device + Diagnostic Industry Article "This Company's False Compliance With CISPR 11 Resulted in a $12 Million FCA...

Life Sciences Entrepreneur Sourcebook | Intellectual Property: What It Is and Why You Should Care

Legal Alert: What to Know About the USPTO's Duty of Candor Guidance Regarding FDA Submissions

Biosimilars 2021 Year in Review

IP and Cannabis: The Current Landscape

5G Developments: From Rollout to Regulation